Order Article Reprints

Ezpeleta G, Navascués A, Viguria N, Herranz-Aguirre M, Juan Belloc SE, Gimeno Ballester J, Muruzábal JC, García-Cenoz M, Trobajo-Sanmartín C, Echeverria A, et al. Effectiveness of Nirsevimab Immunoprophylaxis Administered at Birth to Prevent Infant Hospitalisation for Respiratory Syncytial Virus Infection: A Population-Based Cohort Study. Vaccines. 2024; 12(4):383. https://doi.org/10.3390/vaccines12040383

Ezpeleta, Guillermo, Ana Navascués, Natividad Viguria, Mercedes Herranz-Aguirre, Sergio Enrique Juan Belloc, Juan Gimeno Ballester, Juan Carlos Muruzábal, Manuel García-Cenoz, Camino Trobajo-Sanmartín, Aitziber Echeverria, and et al. 2024. "Effectiveness of Nirsevimab Immunoprophylaxis Administered at Birth to Prevent Infant Hospitalisation for Respiratory Syncytial Virus Infection: A Population-Based Cohort Study" Vaccines 12, no. 4: 383. https://doi.org/10.3390/vaccines12040383

Ezpeleta, G., Navascués, A., Viguria, N., Herranz-Aguirre, M., Juan Belloc, S. E., Gimeno Ballester, J., Muruzábal, J. C., García-Cenoz, M., Trobajo-Sanmartín, C., Echeverria, A., Martínez-Baz, I., Vera-Punzano, N., Casado, I., López-Mendoza, H., Ezpeleta, C., & Castilla, J. (2024). Effectiveness of Nirsevimab Immunoprophylaxis Administered at Birth to Prevent Infant Hospitalisation for Respiratory Syncytial Virus Infection: A Population-Based Cohort Study. Vaccines, 12(4), 383. https://doi.org/10.3390/vaccines12040383